HOLON, Israel, Jan. 14, 2019 /PRNewswire/ -- Compugen Ltd. ( CGEN ), a clinical-stage cancer immunotherapy company and leader in predictive target discovery , today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, will be featured in a trial-in-progress poster at The ASCO-SITC Clinical Immuno-Oncology Symposium, taking place February 28-March 2, 2019, in San Francisco, CA

September 30, 2018
Total current assets - 44,490K$
Net loss for 3M - 3,111K$
A low risk for Offering before ASCO-SITC Clinical Immuno-Oncology Symposium.

support at 3.29 (Possibility for a bullish flag pattern)
In today Avg 3.41 (Second cycle)

Not for any suggestion - very risky.


Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out